Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

December 6th 6:00 – 8:30 p.m.

- Executive Session 6:00 - 6:30
- Introductions and Approval of DUR Board Minutes 6:30 - 6:35
  (Public Comment Prior to Board Action)
- DVHA Pharmacy Administration Updates 6:35 - 6:40
  - Updates
- Medical Director Update 6:40 – 6:45
  - Clinical Programs Update
  - Prescriber Comments
- Follow-up Items from Previous Meetings 6:45 – 6:45
- RetroDUR/DUR 6:45 – 6:55
  - Introduce: Methadone use after Prior Authorization Implementation
- Review of Newly-Developed/Revised 6:55 – 7:40
  (Public comment prior to Board action)
  - ADHD and Cataplexy Medications: Miscellaneous (1/1/17)
  - Anticoagulants: Injectable (1/1/17)
  - Anti-hypertensives: ARB, ARB/CCB Combo (1/1/17)
  - Anti-infective: Cephalosporins 3rd Generation (1/1/17)
  - Epinephrine Auto Injector (1/1/17)
  - Gout Agents (1/1/17)
  - Hepatitis C Agents (1/1/17)
  - Lipotropics: Fibric Acid Derivatives (1/1/17)
  - Ophthalmic: Antibiotics, Antihistamines, Topical Corticosteroids, Glaucoma Agents, NSAID’s (1/1/17)
  - Renal Disease: Phosphate Binders (1/1/17)
  - Urinary Antispasmodics (1/1/17)
  - Vaginal Anti-infective (1/1/17)

- Clinical Update: Drug Reviews 7:40 – 7:40
  (Public comment prior to Board action)
  - None

Abbreviated New Drug Reviews
Full New Drug Reviews

- Cinqair® Inj (reslizumab) (included in the Immunologic Therapies for Asthma Therapeutic Drug Class Review)
- Cholbam® Capsules (cholic acid) (included in the Bile Salts Therapeutic Drug Class Review)
- Ocliva® Tablets (obeticholic acid) (included in the Bile Salts Therapeutic Drug Class Review)

New Managed Therapeutic Drug Classes 7:40-8:00
(Public comment prior to Board action)
- Immunologic Therapies for Asthma
- Bile Salts and Biliary Agents

Therapeutic Drug Classes – Periodic Review 8:00 – 8:25
(Public comment prior to Board action)
- Antivirals, Oral
- H. Pylori
- Antifungals, Oral
- Botulinum Toxins

Review of Newly-Developed/Revised 8:25 – 8:30
(Public comment prior to Board action)

General Announcements 8:25 – 8:30
Selected FDA Safety Alerts

FDA analyses conclude that Xarelto clinical trial results were not affected by faulty monitoring device

Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement - Risks Associated With Abuse and Dependence

Adjourn 8:30